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Abstract
Amyloid-β (Aβ), a neurotoxic peptide, is linked to the onset of Alzheimer’s disease (AD). 
Increased Aβ content within neuronal cell mitochondria is a pathological feature in both human 
and mouse models with AD. This accumulation of Aβ within the mitochondrial landscape 
perpetuates increased free radical production and activation of the apoptotic pathway. Human 
Presequence Protease (hPreP) is responsible for the degradation of mitochondrial amyloid-β 
peptide in human neuronal cells, and is thus an attractive target to increase the proteolysis of Aβ. 
Therefore, it offers a potential target for Alzheimer’s drug design, by identifying potential 
activators of hPreP. We applied structure-based drug design, combined with experimental 
methodologies to investigate the ability of various compounds to enhance hPreP proteolytic 
activity. Compounds 3c & 4c enhanced hPreP-mediated proteolysis of Aβ (1–42), pF1β (2–54) and 
fluorogenic-substrate V. These results suggest that activation of hPreP by small benzimidazole 
derivatives provide a promising avenue for AD treatment.
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1. Introduction
Mitochondrial dysfunction is an early pathologic feature of Alzheimer’s disease (AD). AD-
affected brain shows abnormalities in mitochondrial structure and function including 
hypometabolism, increased production of reactive oxygen species (ROS) and decreased 
respiration potential [1–8]. Amyloid-β (Aβ) is a major component of amyloid pathology 
contributing to the pathogenesis of AD. Recent studies from our and other independent 
groups demonstrate accumulation of Aβ in mitochondria in aged and AD brain [6, 9–17]. Aβ 
enters mitochondria through the protein translocase of the outer membrane (TOM) 
machinery [15]. The receptor for advanced glycation end product (RAGE) also aids in 
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localization and transport of mitochondrial Aβ. Neurons lacking RAGE exhibit lowered 
mitochondrial Aβ accumulation and are protected from Aβ-induced mitochondrial 
dysfunction [11]. The degree of mitochondrial Aβ accumulation correlates to mitochondrial 
and synaptic dysfunction as well as cognitive decline observed in AD mouse models. Excess 
Aβ disrupts normal mitochondrial function thereby inducing oxidative stress, lowered ATP 
content, and a rise in intercellular Ca2+ [14, 16, 18, 19] [20]concentration. Subsequently, an 
increase in mitochondrial Aβ intensifies its interaction with mitochondrial protein including 
amyloid binding alcohol dehydrogenase (ABAD)[14, 21] and cyclophilin-D (CypD)[16, 22], 
exaggerating mitochondrial and neuronal stress. Thus, mitochondria provide a direct site for 
Aβ-induced mitochondrial damage and reducing Aβ accumulation or increasing Aβ 
clearance in mitochondria may be a therapeutic strategy for prevention and treatment of AD 
in particular during early stage.
Human Presequence protease (hPreP), a 114kDa human zinc metalloprotease 1, (hMP1), 
[23] is located in the mitochondrial matrix [24] and belongs to the pitrilysin M16C family of 
peptidases containing an inverted zinc-binding motif, HXXEH [25]. hPreP is an ATP-
independent protease that consists of 1,037 amino acids (AAH05025) and is encoded by the 
PITRM1 gene located on chromosome 10 [23]. The presence of human PreP (hPreP) in 
mitochondrial matrix is confirmed by proteomics 17.31% amino acid sequence [28] and is 
involved in the degradation of small-unstructured peptides. Importantly, hPreP was found to 
be the novel protease responsible for the degradation of mitochondrial Aβ in the human AD-
affected brain [15, 26, 27].
Although it is a functional analogue to insulin degrading enzyme (IDE), unlike IDE, PreP 
cannot degrade insulin [24, 28]. It does however degrade Aβ, but the degradation of Aβ 
peptides by recombinant hPreP results in several fragments that are unique only to hPreP. 
Despite the fact that the three dimensional structures of PreP [29] and IDE [30] are very 
similar, IDE harbors an exosite in the catalytic chamber, which is hypothesized to unfold 
small proteins. The corresponding site is absent in PreP, thereby preventing the degradation 
of small folded proteins. This makes PreP a better candidate than IDE for clear Aβ since it 
does not degrade the important insulin protein [24, 28]. The available literature suggests that 
decreased PreP activity in AD-affected human and mouse neuronal mitochondrial matrixes 
leads to Aβ aggregation followed by apoptotic cell death. Introduction of hPreP allows for 
the degradation of Aβ and could prove vital to the understanding of AD pathology.
The literature suggests that increased ROS production [31] is an early indicator of AD 
pathogenesis and that increased ROS negatively impacts the ability of hPreP to degrade Aβ. 
In a study, using five to twelve month-old mice [24], PreP proteolytic activity is decreased 
with age and Aβ-rich mitochondria and AD-affected brain, indicating that there may be a 
link between overall Prep activity, Aβ accumulation, and age.
We built a three dimensional structural homologous model of hPreP based on the 2.1Å 
crystal structure of AtPreP [28], in which two cysteines are in close proximity to each other 
allowing for the possible formation of a disulfide bond under oxidizing conditions inhibiting 
hPreP activity. A recent study demonstrated that hPreP inactivation by H2O2 is not due to 
the formation of a disulfide bridge, but is instead due to the methionine residues that are 
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readily oxidized to produce methionine sulfoxide ROS. Conserved methionine residues play 
an important role in protecting proteins from oxidative inactivation by scavenging oxidizing 
agents and limiting the damage to catalytically essential residues [32]. This data strongly 
supports the potential of hPreP to act as a target in the development of AD treatments.
The goal of the present study was to develop small molecules that regulate hPreP function to 
enhance degradation and clearance of mitochondrial small unstructured peptides including 
Aβ. We utilized structure based virtual screening to identify novel compounds that bind to 
the hPreP active site, with the goal of enhancing proteolysis to specific substrates.
2. Results and Discussion
2.1. PreP activators design
It is also well known from the literature that benzimidazole derivatives have antioxidant 
activity. [34–36] It is also possible that our benzimidazole derivatives could potentially 
reduce ROS levels. A series of compounds were designed and tested to determine their 
potential use in AD treatment. Each novel compound was subjected to a structure based 
virtual screening approach to identify their potential to bind with the hPreP active site. The 
drug like properties of newly designed compounds was predicted by QSAR and molecular 
docking studies. The QSAR analysis helped to derive highly applicable models that allowed 
for the modification of novel reactive molecules. Preliminary structure–activity relationship 
(SAR) studies indicated that benzimadazole moiety is required for the activation of hPreP 
activity. This is consistent with the benzimadazole derivative described in the first examples 
of computer-aided exploration into IDE regulators which can be used for the treatment of 
AD.[33] The newly designed compounds proposed in this study could serve as initiators for 
lead optimization studies, which could ultimately lead towards the design of compounds for 
the treatment of Alzheimer’s disease.
2.2. Synthesis
We synthesized a series of novel benzimidazole derivatives (3a–e & 4a–e, shown in Scheme 
1), with various aromatic aldehydes, 4-nitrobenzene-1,2-diamine (2) by mixing with 
trimethylsilyl chloride (TMSCL, 1mol %) in water (5mL). The reaction mixture was stirred 
at room temperature for 8–12 h. TMSCl, an extremely efficient catalyst, was used in the 
preparation of compounds 4a–e. All reactions were carried out following this general 
procedure. Compounds 3a–e were prepared through the reaction of various aromatic 
aldehydes with 4-nitrobenzene-1,2-diamine in trifluoroethanol (TFE) at room temperature. 
The chemical structures of the new compounds were confirmed using: IR, 1H NMR, 13C 
NMR spectral data and HRMS, the data for which are presented in the Experimental 
Protocols section. We observed characteristic IR absorption readings in regions at: 3475–
3371 cm−1 and 3342–3330−1, for: N–H [37, 38], O–H [39, 40], respectively. In the 1H NMR 
spectra of compounds 3a–e & 4a–e, the chemical shifts of aromatic hydrogen’s on the 
phenyl ring appeared as doublets in region and multiplets of 6.96–7.92 and 6.75–7.94 
respectively [41, 42]. The O–H hydrogen resonated as a broad singlet in region 11.59–10.97. 
In 13C NMR, we observed chemical shifts for compounds 3a–e & 4a–e in expected regions.
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2.3. Quantitative structure-activity relationship (QSAR) descriptors
The three dimensional structures of our compounds (3a–e & 4a–e) were constructed using 
the builder interface of the molecular operating environment (MOE) program and subjected 
to energy minimization using the Merck molecular Force Field 94x (MMFF94x)[43, 44]. All 
items were set to default with an RMS gradient of 0.01 kcal/mol and an RMS distance of 0.1 
A°. We subjected the resultant models to a systematic conformational search. Using the 
above conformations, we studied QSAR descriptors, meeting the Lipinski criteria for safe 
drugs [45, 46]. Our designed compounds have a molecular weight less than 500 Da with 
exception of compounds 4c, 4d and 4e. Compound 3a had the lowest molecular weight 
(361.35 Da), while compound 4c had the highest molecular weight (702.90 Da). There were 
less than 5 numbers of hydrogen bond donors and less than 10 hydrogen bond acceptors for 
all compounds. LogP values were below 5, indicating that all are non-toxic to the host 
system. Molar refractivity was in-between 40–150, the optimal range. Characterization of 
remaining descriptors such as surface area, volume, hydration energy, polarizability and 
energy levels were also encouraging showing suitable feature in binding domains of the 
targets and inhibitors suggesting the potential safety and efficacy of these targets (Table 1).
2.4. Molecular modeling [47, 48]
Molecular modeling studies has often been proven to be a powerful tool for rationalizing 
ligand-receptor interactions and for making this information available to virtual screening 
techniques. The ligand database that was developed from the total set of ten compounds was 
docked into the specified binding domain of the hPreP receptor. As we know that PreP is 
present in Arabidopsis thaliana, and is responsible for the degradation of mitochondrial 
presequences and elimination of chloroplast transit peptides generated after organelle 
precursor protein import and processing [49–51], we identified hPreP binding sites using the 
crystal structure of AtPreP (http://www.rcsb.org/pdb, PDB ID: 2FGE), with residues: 
Asn136, Ala137, Phe138, Thr139, Ala140, Glu205, Try906, Arg900, Gln222. A total of 30 
conformations were generated for each ligand-receptor complex and among them, the 
conformation with least docking score was considered for further analysis. The MOE 
interaction of all ligand molecules in the binding domain cavity was analyzed. The ligand-
receptor complexes were analyzed by both London G free energy approximations and E 
interaction energies. Compounds 3c had the best docking score of −8.6 kcal/mole, followed 
by docking scores for compound 4c (−8.3 kcal/mole). Interestingly, compound 3c formed an 
arene-hydrogen bond with Gly121 (Figure 1). These two ligands had the best docking scores 
with stable ligand interactions and are composed of primarily non-polar pi-stacking 
interactions between Phe 123, Phe124, Try906, Try921, with minimal H-bonding and Zn+2 
coordination (Figure 1).
2.5. Pharmacophore Model: PreP activators 5 Feature Pharmacophore Model[28, 47, 48]
Using the Pharmacophore five-feature model, shown in Figure 3, we selected 4 out of 10 
compounds as ‘hit’s, namely compounds 3c, 3d, 4c and 4d. Compounds 3c and 4c exhibited 
strong binding against hPreP. Based on the number of hits, the predictive capacity of active 
hits is at least 50% (Figure 2).
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2.6. Evaluation of enzymatic activity of hPreP
Compounds with small molecular weights are necessary to boost hPreP activity and provide 
therapeutic protection against AD. The literature suggests that hPreP degrades mitochondrial 
targeting peptides that are cleaved off by mitochondrial processing peptidases following 
import to mitochondria. PreP’s critical role in the degradation of mitochondrial Aβ is 
significant as accumulation of mitochondrial Aβ is directly linked to Aβ-induced 
mitochondrial toxicity. Further, hPreP also degrades non-Aβ substrates such as pF1β, a 53 
amino acid long mitochondrial presequence peptide, and substrate V, a 9 amino acid 
fluorogenic peptide. Even though these peptides have slightly different properties (Aβ 
peptides are negatively charged, and pF1β are positively charged), hPreP degrades both with 
similar efficiency. To our knowledge, compound 3c & 4c are the first drug-like compounds 
shown to stimulate hPreP-mediated proteolysis of various substrates.
To study the regulatory effect of our target compounds (3a–e & 4a–e) on the proteolytic 
activity of hPreP, we selected three substrates of different lengths and properties for use in 
an in vitro degradation assay: 1)Aβ (1–42); 2) the presequence of ATP synthase F1β subunit 
pF1β (2–54); 3) and a fluorescent peptide known as substrate V. Activity assays were 
initially set at a concentration of 100 μM for all studied molecules in order to identify the 
effect of those compounds on overall hPreP activity. We quantified hPreP activity by 
monitoring the change in fluorescence for proteolysis of fluorogenic-substrate V and 
monitored the efficacy of degradation of Aβ (1–42) & pF1β, using immunoblotting for Aβ 
with NuPAGE 12% Bis-tris gel assay.
Analysis of compounds showed that 3c & 4c increased proteolytic activity of hPreP against 
biotin labeled Aβ (1–42), significant up to a 1μM concentration when compared to other 
analogs. Compounds 3c & 4c effectively facilitated the degradation of Aβ at more efficient 
levels than hPreP alone (Figure 3A & 4A). We observed degenerated and dose dependent 
immunoreactive biotin Aβ bands due to the enhanced proteolytic activity of hPreP at various 
concentrations of compound 3c & 4c (Figure 3C, D & 4C, D), with no Aβ immunoreactive 
bands at 100μM (Figure 3D & 4D, lane 5), compared to hPreP alone. Analysis for the effect 
of compounds on hPreP activity showed that 3c increased the hPreP -mediated Aβ 
degradation by 1.7 (42%) & 4c by 2.1 folds (54%) (Figure 9A).
Next, we analyzed an EC50 value of each molecule that enhanced hPreP activity using a 
dose response assay, where specific activity of hPreP was measured with different 
concentrations of the lead compounds and then the plot was fit to prism nonlinear 
regression, a log (agonist) vs. normalized response equation. Calculated EC50 values for 3c 
& 4c were 0.713 μM and 0.402 μM, respectively (Figure 3B & 4B).
In the case of non-Aβ substrates, hPreP also degraded pF1β and compounds 3c & 4c showed 
significant proteolytic activity of hPreP in degrading pF1β even at 1μM concentration. 
Significant changes in pF1β degradation were observed with compounds 3c & 4c when 
compared to hPreP alone (Figure 5A & 6A). In figures 5C & 6C the presence of degenerated 
& dose dependent immunoreactive biotin pF1β bands, indicate enhanced proteolytic activity 
of hPreP with different concentrations of compounds 3c & 4c. Compounds 3c & 4c 
increased hPreP-mediated pF1β degradation by 1.8 (45%) & 2.2 folds (55%) respectively 
Vangavaragu et al. Page 5













(Figure 9B). EC50 values for 3c & 4c were measured at 0.012 & 0.601μM, respectively 
(Figure 5B & 6B).
Further, we performed kinetic studies using Substrate V, a fluorogenic peptide 9 amino acids 
long containing the fluorescent group 7-methoxycoumarin and the quencher group 2, 4-
dinitrophenyl, thus, providing light emission upon cleavage of the peptide bond between 
these two groups. Compounds, 3c & 4c increased the initial rate of proteolysis activity of 
hPreP the most, specifically by 1.5 and 1.8 folds, respectively at 1μM (Figures 7A & 8A). 
Further, the EC50 values for 3c & 4c were 0.152 & 0.057 μM, respectively (Figures 7B & 
8B).
Interestingly, condensation of 5-bromo-2-hydroxy benzaldehyde with nitro o-phenelene 
diamine plays a crucial role in bioactivity of our compounds 3c & 4c. Introduction of a 5-
bromo-2-hydroxy group (3c into the benzimidazole ring) enhanced the proteolytic activity of 
hPreP against biotin Aβ (1–42), pF1β (2–54) and substrate V. The same correlation was also 
observed in compound 4c against these three aforementioned substrates. It is clear that the 
presence of a bromo group on the aromatic ring is essential for improving hydrophilic 
interactions between the compound and hPreP. Substitution of the fluoro, methoxy & 
hydroxy in the aromatic aldehyde caused a substantial loss of proteolytic activity of hPreP. 
These results suggest that the compounds with halogen atoms (bromo) that underwent 
hydroxyl substitution on their phenyl ring(s) (3c & 4c) were the most potent and selective 
activators for the proteolytic activity of hPreP. Our results clearly indicate that 
benzimidazole analogues shed new light on the design and understanding of selective 
proteolytic enzyme activators, which will enable the synthesis of our scaffold into clinically 
useful anti-Alzheimer’s drugs.
3. Conclusion
In the present study, we designed novel benzimidazole derivatives according to their binding 
modes inside the hPreP active site. Amongst them, we selected compounds that obeyed the 
Lipinski’s “rule of five.” This is extensively used to screen for the drug-like properties. Our 
novel compounds behaved like hPreP agonists, with compounds 3c & 4c being most active. 
Introduction of a 5-bromo-2-hydroxy benzaldehyde group increased potency resulting in the 
4-bromo-2-(1-(5-bromo-2-hydroxybenzyl)-5-nitro-1H-benzo[d]imidazol-2-yl) phenol & 
2,2′-((2-(5-bromo-2-hydroxyphenyl)-5-nitro-1H-benzo[d]imidazole-1,3(2H) 
diyl)bis(methylene))bis(4-bromophenol), which are the most active compounds (at 100 μM) 
and seem to be good agonists of hPreP with EC50 in the low μM range.
Together with biological results (indicating that the synthesized benzimidazole-based 
compounds possess agonist activity with hPreP) and the results of the docking studies and 
regulating activities, we conclude that compounds 3c & 4c are appropriate scaffolds for the 
development of new hPreP regulators. Further investigation of the effect of these 
benzimadazole derivatives on hPreP agonist activity will move the development of new 
agents for the treatment of AD forward towards translation to clinical use.
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4. Materials and Methods
4.2. Chemistry
4.2.1. General—All reagents were commercially available and used without further 
purification. Melting points were determined in open capillary tubes using a Laboratory 
Devices Mel-Temp apparatus and are uncorrected. 1H and 13C NMR spectra were recorded 
in d6-DMSO on a Bruker DRX-500 spectrometer operating at 500 MHz, and 125 MHz, 
respectively, and calibrated to the solvent peak. Abbreviations used for the split patterns of 
proton NMR signals are: singlet (s), doublet (d), triplet (t), quartet (q), quintet (qui), 
multiplet (m) and broad signal (br). High-resolution mass spectrometry (HRMS) was 
recorded on a LCT Premier Spectrometer.
4.2.2. General procedure for the preparation of compounds (3a–3e)—A mixture 
of aromatic aldehyde (2 mmol), 4-nitrobenzene-1, 2-diamine (1 mmol, 2 equiv), and TFE 
(1mL) was stirred magnetically at room temperature for 1h. The progress of the reaction was 
monitored using TLC (hexane: ethyl acetate, 1:1 v/v). After completion of the reaction, the 
reaction mixture was dissolved in EtOAc (3 mL), adsorbed on silica gel (0.5 g, 230–400 
mesh), and concentrated under rotary vacuum evaporation. The resultant solid mass was 
charged onto a flash chromatography column and eluted with hexane-EtOAc (85:15) to 
afford the title compounds.
4.2.3. 4-(1-(4-Hydroxybenzyl)-5-nitro-1H-benzo[d]imidazol-2-yl) phenol (3a)—
Light color solid, 77% yield; mp: 185–186 °C; Rf 0.22; (hexane: ethyl acetate, 1:1 v/v). IR: 
3234, 3050, 2902, 2864, 2362, 1712, 1668, 1529, 1431, 1350, 1257, 1091, 1031, 748 
cm−1; 1H NMR (DMSO-d6) ™ 10.15 (s, 1H), 9.46 (s, 1H), 8.45 (d, J = 3.75 Hz, 1H), 
8.15-8.13 (m, 1H) 7.84 (d, J = 3.75 Hz, 1H), 7.67-7.63 (m, 2H), 6.94-6.91 (m, 2H), 
6.69-6.66 (m, 2H), 5.61 (s, 2H). 13C NMR (DMSO-d6)™ 159.6, 158.6, 156.8, 147.6, 142.6, 
135.4, 130.9, 127.5, 126.4, 119.6, 119.0, 117.8, 115.7 (J = 15.0 Hz), 47.6. HRMS cald for 
C20H16N3O54 (M+H) 362.1132; found 362.1141 (TOF MS ES+).
4.2.4. 1-(4-Fluorobenzyl)-2-(4-fluorophenyl)-5-nitro-1H-benzo[d]imidazole (3b)
—Yellow solid, 88% yield; mp: 201–203 °C; Rf 0.32; (hexane: ethyl acetate, 1:1 v/v). IR: 
3076, 3055, 2948, 2765, 1897, 1610, 1523, 1483, 1329, 1265, 1172, 1110, 954, 823, 748 
cm−1; 1H NMR (DMSO-d6)™ 8.63-8.61 (m, 1H), 8.22-8.18 (s, 1H), 7.86-7.79 (m, 3H) 
7.45-7.40 (t, 2H), 7.15-7.02 (m, 4H), 5.76-5.68 (m, 2H). 13C NMR (DMSO-d6) ™ 164.3(d, 
J = 7.5 Hz), 162.4, 160.4(d, J = 3.75 Hz), 157.2, 156.1, 146.9, 143.2, 142.9, 141.6, 140.2, 
135.3, 132.4(d, J = 3.75 Hz), 132.2(d, J = 2.5 Hz), 131.7, 128.3(d, J = 8.75 Hz), 119.6, 
118.4, 118.0, 116.1, 115.9, 115.7, 115.6, 115.4, 111.7, 108.1, 47.2 (d, J = 15 Hz). HRMS 
cald for C20H14F2N3O2 (M+H) 366.1052; found 366.1054 (TOF MS ES+).
4.2.5. 4-Bromo-2-(1-(5-bromo-2-hydroxybenzyl)-5-nitro-1H-benzo[d]imidazol-2-
yl) phenol (3c)—White crystals, 78% yield; mp: 226–228 °C; Rf 0.32; (hexane: ethyl 
acetate, 1:1 v/v). IR: 3475, 3342, 3055, 2989, 2893, 2304, 1903, 1629, 1610, 1579, 1488, 
1434, 1348, 1222, 1176, 977, 896, 748 cm−1; 1H NMR (DMSO-d6) ™ 11.60 (s, 2H), 8.92 (s, 
2H), 8.12 (d, 1H) 7.96-7.93 (m, 2H), 7.56-7.53 (m, 2H), 6.96 (d, J = 10.0 Hz, 2H), 6.81-6.78 
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(m, 2H). 13C NMR (DMSO-d6) ™ 159.1, 158.3, 150.3, 136.0, 135.5, 133.6, 132.5, 124.4, 
122.6, 199.0, 144.1, 113.1, 110.4. HRMS cald for C20H13Br2N3O4 (M+H); 517.9351, found 
517.9352 (TOF MS ES+).
4.2.6. Methyl 2-hydroxy-5-(1-(4-hydroxy-3-(methoxycarbonyl)benzyl)-5-
nitro-1H-benzo[d]imidazol-2-yl)benzoate (3e)—Yellow solid, 86% yield; mp: 265–
267 °C; Rf 0.20; (hexane: ethyl acetate, 1:1 v/v). IR: 3371, 3055, 2950, 2767, 1903, 1627, 
1612, 1487, 1265, 1176, 977, 896, 817, 738 cm−1; 1H NMR (DMSO-d6) ™ 11.06 (s, 2H), 
8.88-8.68(m, 2H), 8.45-8.38 (m, 5H), 8.15-8.13 (m, 1H) 7.78 (d, J = 5.0 Hz, 2H), 7.24 (d, J 
= 10.0 Hz, 2H), 3.96 (s, 6H). 13C NMR (DMSO-d6) ™ 167.8, 162.0, 154.0, 143.1, 141.2, 
137.1, 133.8, 130.0, 118.7, 118.5, 114.7, 114.4, 111.1, 52.6. HRMS cald for C24H20N3O8 
(M+H) 478.1250; found 478.1259 (TOF MS ES+).
4.2.7. General procedure for the preparation of compounds (4a–4e)—To a 
stirred solution aromatic aldehyde (3 mmol), 4-nitrobenzene-1, 2-diamine (1 mmol, 2 
equiv), was added in the presence of trimethylsilylchloride dissolved in water (5 mL). The 
reaction mixture was stirred for 8–12 h at room temperature. The progress of the reaction 
was monitored by TLC (hexane: ethylacetate1:1). After completion of the reaction, a solid 
was formed. The solid was filtered off, washed with water, and dried. It was purified by 
silica gel column chromatography eluting with hexane: ethyl acetate (95:5) mixture to afford 
the title compounds.
4.2.8. 4,4′-((2-(4-Hydroxyphenyl)-5-nitro-1H-benzo[d]imidazole-1,3(2H)-
diyl)bis(methylene)) diphenol (4a)—Light orange color solid; mp: 224–226 °C; Rf 
0.24; (hexane: ethyl acetate, 1:1 v/v). IR: 3234, 3103, 2902, 2796, 2362, 1712, 1668, 1529, 
1350, 1091, 1031, 881, 738 cm−1; 1H NMR (DMSO-d6) δ 10.23 (s, 1H), 9.45 (s, 2H), 8.48 
(d, J = 3.75 Hz, 2H), 8.15-8.13 (m, 2H) 7.68-7.62 (m, 4H), 7.01–7.06 (m, 3H), 6.82–6.89 
(m, 3H), 6.71-6.69 (m, 2H), 5.56 (s, 4H). 13C NMR (DMSO-d6) δ 160.3, 159.2, 158.0, 
148.1, 142.8, 136.1, 131.2, 128.6, 127.5, 120.0, 119.4, 118.5, 116.8 (J = 15.0 Hz), 48.1. 
HRMS cald for C27H24N3O5 (M+H) 470.1716; found 470.1761(TOF MS ES+).
4.2.9. 1,3-Bis(4-fluorobenzyl)-2-(4-fluorophenyl)-5-nitro-2,3-dihydro-1H-
benzo[d]imidazole (4b)—Yellow solid, 92% yield; mp: 196–198 °C; Rf 0.30; (hexane: 
ethyl acetate, 1:1 v/v). IR: 3099, 3055, 2927, 2761, 1895, 1730, 1610, 1579, 1483, 1344, 
1265, 1174, 1110, 896, 748 cm−1; 1H NMR (DMSO-d6) δ 8.68-8.59 (m, 2H), 8.28-8.22 (s, 
2H), 7.70-7.59 (m, 5H) 7.48-7.41 (m, 4H), 7.16-7.01(m, 4H), 5.80-5.71 (m, 4H). 13C NMR 
(DMSO-d6) δ 165.2, 163.2, 161.1(d, J = 3.75 Hz), 158.1, 158.1, 142.1, 140.5, 139.8, 138.8, 
138.2, 136.3, 131.4(d, J = 3.75 Hz), 131.1, 129.2, 127.3, 120.6, 119.3, 118.2, 116.8, 115.9, 
115.2, 114.2, 113.2, 110.1, 107.1, 48.3 (d, J = 15 Hz). HRMS cald for C27H21F3N3O2 (M
+H) 476.1586; found 476.1591 (TOF MS ES+).
4.2.10. 2,2′-((2-(5-Bromo-2-hydroxyphenyl)-5-nitro-1H-
benzo[d]imidazole-1,3(2H) diyl)bis(methylene))bis(4-bromophenol) (4c)—White 
crystals, 82% yield; mp: 256–257 °C; Rf 0.28; (hexane: ethyl acetate, 1:1 v/v). IR: 3330, 
3236, 2927, 2883, 1924, 1714, 1668, 1568, 1525, 1346, 1253, 1091, 1051, 881, 738, 698 
cm−1; 1H NMR (DMSO-d6) ™ 11.59 (s, 2H), 8.94 (s, 2H), 8.12 (d, 2H) 7.96-7.94 (m, 4H), 
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7.56-7.54 (m, 2H), 6.96 (d, J = 10.0 Hz, 2H), 6.80-6.78 (m, 6H). 13C NMR (DMSO-d6) ™ 
159.1, 158.3, 150.3, 136.0, 135.5, 133.6, 132.5, 124.4, 122.6, 199.0, 144.1, 113.1, 110.4. 
HRMS cald for C27H20Br3N3O5 (M+H) 702.8953; found 702.8922 (TOF MS ES+).
4.2.11. Dimethyl 5,5′-((2-(4-hydroxy-3-(methoxycarbonyl)phenyl)-5-nitro-1H-
benzo[d]imidazole-1,3(2H)-diyl)bis(methylene))bis(2-hydroxybenzoate) (4e)—
White crystals, 72% yield; mp: 286–288 °C; Rf 0.18; (hexane: ethyl acetate, 1:1 v/v). IR: 
3055, 2989, 2950, 1629, 1579, 1587, 1534, 1487,1222, 1176, 977, 817, 750 cm−1; 1H NMR 
(DMSO-d6) ™ 10.97 (s, 3H), 8.81 (d, J = 5.0 Hz, 3H), 8.41 (m, 2H), 8.32-8.30 (m, 1H), 
8.15-8.13 (m, 1H) 8.00 (d, J = 5.0 Hz, 3H), 7.92 (d, J = 5.0 Hz, 1H), 7.14-7.11 (m, 3H), 
6.77-6.75 (m, 4H), 3.94 (s, 9H). 13C NMR (DMSO-d6) ™ 168.5, 162.2, 158.6, 150.9, 135.9, 
135.0, 134.2, 132.4, 127.8, 124.1, 118.0, 113.8, 113.0, 112.5, 52.6. HRMS cald for 
C33H30N3O11 (M+H) 644.1880; found 644.1852 (TOF MS ES+).
4.1.1. Preparation of human PreP homology model [28]—A Blast (NCBI, 
www.ncbi.nih.gov) database search of the PDB Databank revealed the optimal starting 
template structure for human PreP as a zinc metalloprotease ((PDB:http://www.rcsb.org/
pdb, PDB ID: 2FGE). Sequence homology construction of the human PMP1 enzyme 
sequence based on 2FGE structure was carried out using a MOE protein homology 
algorithm. Hydrogens were added to the resulting 3D structure based on a pH of 7 and a salt 
concentration of 0.1 M. pH of 7. The implicit born solvation model and a non-bonded cut off 
value of 10–12 were incorporated in the MMFF94x force field. The complete structure was 
energy minimized to a gradient cut off value of 0.05. Molecular dynamic simulations were 
carried out at a constant temperature of 300° K for a heating time of 10 pico seconds. 
Simulations were carried out for 10 nano seconds. The time step was considered as 0.001 
pico seconds and the temperature relaxation time was set to 0.2 pico seconds. Position, 
velocity and acceleration were saved every 0.5 pico seconds.
4.1.2. Prediction of Binding site for Ligands—The binding site of hPreP was 
elucidated through the crystal structure of AtPreP (PDB:http://www.rcsb.org/pdb, PDB ID: 
2FGE). In our case, we used a proximity radius of r </= 10 Ao. A confirmatory approach for 
determining the binding site of these novel drug-like candidates involved use of Alpha Site 
Finder methodology [Edelsbrunner, et al. “Measuring Proteins and Voids in Proteins”,. 
Proceedings from the 28th International Conference on Systems Science, 256–264(1995)], 
incorporated into the Chemical Computing Group’s the molecular modeling software. This 
algorithm calculates and displays potential regions of tight atomic packing on a protein 
surface.
4.1.3. Molecular Docking [24, 25]—A conformational set was generated for each of our 
ligand molecules using the LowModeMD Search algorithm within the MOE program. This 
involves a short molecular dynamics simulation using velocities with low kinetic energy on 
high-frequency vibrational modes. An iteration limit of 5000 (maximum number of attempts 
to generate a new conformation) and a minimization limit of 250 (maximum number of 
minimization steps) were set to control the number of conformations generated. Each 
generated conformation was docked into the specified binding domain of the human PreP 
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receptor. We analyzed interaction of all ligand molecules in the binding domain cavity using 
ligand interaction study in the MOE software. The ligand-receptor complexes were analyzed 
using the sum of the following two scoring functions: (i) London ⊗G free energy 
approximations and (ii) interaction energies, ⊗E. Ligands that bound with the lowest 
docking score were considered for further analysis.
4.1.4. Pharmacophore Model—A pharmacophore defines features as well as locations 
of important binding interactions between a ligand and its receptor. Our five-feature 
pharmacophore model was constructed by overlapping the top two ligand candidates 
(compounds 3c and 4c) that had the strongest binding affinities. The Unified scheme within 
MOE was used to define the unique features (2 H-bond [Don/Acc] and 3 aromatic centers 
[Aro]). The locations of these features were determined by inspection of strong interactions 
of these two compounds at the PreP active site.
4.3. Degradation assays
For the analysis of the novel compounds as chemical regulators for hPreP activity, we 
performed degradation assays with biotin-labeled Aβ (1–42) and F1β (2–54) [36] 
presequence peptides in degradation buffer (20mM HEPES-KOH pH 8.0) with10mM 
MgCl2, 1μg of purified hPreP and 0.02μg of a substrate at various concentrations (0.00001–
100μM). Compounds were incubated for 2.5 h at 373C. Reactions were stopped by the 
addition of 4× sample buffer, and then analyzed on NuPAGE 12% Bis-Tris gel (Invitrogen, 
CA), and run in 1×MES buffer. Proteins were electrophoretically transferred to 
nitrocellulose membrane HybondTM (Amersham Bioscience) for 1 h at 100V. For pF1β 
identification, the nitrocellulose membrane was blocked overnight in 5% milk-PBS followed 
by incubation with pF1β antibody (1:2000) and detected using horseradish peroxidase-
conjugated anti-rabbit secondary antibody (1:2500) and enhanced chemiluminescence (ECL, 
GE Healthcare). For analyzing the degradation of biotin labeled Aβ (1–42) (biotin- LC- 
Aβ1–40, biotin-LC- Aβ1–42), the nitrocellulose membrane was dried overnight at 253C 
followed by blocking with 2% milk-PBS for 1 h. Immunoblotting was performed with 
ExtraAvidin Peroxidase Conjugate 1:3000 (Sigma) and detection by ECL.
4.4. Degradation of Substrate V by hPrep
To determine the efficiency of these novel compounds as chemical regulators for hPreP 
activity, we used a fluorescence assay with fluorogenic substrate V (7-methoxycoumarin-4-
yl-acetyl-NPPGFSAFK-2, 4-dinitrophenyl, R&D Systems) and measured the kinetics of 
proteolysis. Reaction was carried out in the presence of 1μg hPreP in 20mM HEPES, pH 8.0 
with 10mM MgCl2 mixed with 0.1μg Substrate V and various concentrations (0.00001–
1μM) of our compounds in a final volume of 250μl. The hydrolysis of substrate V was 
measured for 10 minutes using a fluorometer (SpectraMax Gemini) with excitation and 
emission wavelengths set at 320 and 405 nm, respectively. Results are shown as the 
Substrate V degradation rate and averaged over three independent experiments (Figure 7)
4.5. Statistical analysis
Statistical analyses were performed using STATVIEW software. One-way ANOVA was 
used for repeated measures followed by Bonferroni/Dunn Protected Least Significant 
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Difference analysis for post-hoc comparisons. Results are expressed as mean ± Standard 
Error Mean (SEM). Significance was set at p < 0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• We have deigned and synthesized hPreP antagonists for treatment of 
Alzheimer’s Disease.
• Title compounds enhanced hPreP-mediated proteolysis of amyloid beta (Aβ).
• Aβ (1–42), pF1β (2–54) and fluorogenic-substrate V were used as substrates of 
hPreP.
• 3c & 4c showed potent enhancement of hPreP-mediated proteolysis various 
substrates in vitro.
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hPreP binding site for compounds 3c (yellow) and 4c (green). Shown are the interacting 
residues within 5 A° that stabilize the binding of these two compounds. Residues are labeled 
with residue number. The Zn cation ligand coordinates with residues Try906, Glu205, 
His104 and His108. Coordination distances range from 1.0 to 2.6 A°. Interestingly, the (2, 5-
Bz) group on compound 3c appears to be involved with this coordination forming a 
bipyramidal trigonal complex with its OH group. Although the equivalent aromatic hydroxy 
for compound 4c is oriented in the same direction, it is further away (3.6 A°) and forms a 
much weaker bond.
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The predicted active hits for our 5-feature pharmacophore model. Spheres represent the 
important regions in space for tight ligand binding. The two pink regions show H-bonding, 
while orange shows 3 regions that characterize aromaticity. The 4 active hits are identified 
by their “bond stick” colors: 3c (orange), 3d (magenta), 4c (turquoise) and 4d (white).
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Effect of compound 3c on Aβ degradation. (A) Densitometry of Aβ immunoreactive bands is 
shown by analysis using NIH ImageJ software. Determination of proteolytic activity of 
hPreP showing degradation of biotin-Aβ (1–42), pure hPreP protein was incubated with Aβ 
(1–42) and various concentrations of compound 3c, which was then subjected to 
immunoblotting with ExtrAvidin peroxidase conjugated IgG and detection with ECL to 
reveal immunoreactive biotin Aβ. (B) Measurement of increases in hPreP activity for Aβ (1–
42) in the presence of compound 3c at concentrations ranging from 100 to 0.01μM. The 
panels C and D showed the representative gel images.
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Effect of compound 4c on Aβ degradation. (A) Densitometry of Aβ immunoreactive bands is 
shown using NIH ImageJ software. Determination of proteolytic activity of hPreP showing 
degradation of biotin-Aβ (1–42), pure hPreP protein was incubated with Aβ (1–42) and 
various concentrations of compound 4c, which was then subjected to immunoblotting with 
ExtrAvidin peroxidase conjugated IgG and detection with ECL to reveal immunoreactive 
biotin Aβ. (B) Measurement of increased hPreP activity for Aβ (1–42) in the presence of 
compound 4c at concentrations ranging from 100 to 0.01μM. The panel C and D showed the 
representative gel images.
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Effect of compound 3c on pF1β degradation. (A) Densitometry of pF1β immunoreactive 
bands is shown using NIH ImageJ software. Determination of proteolytic activity of hPreP 
showing degradation of pF1β, pure hPreP protein was incubated with pF1β and various 
concentrations of compound 3c, which was then subjected to immunoblotting with antibody 
to F1β and detection with ECL to reveal immunoreactive biotin Aβ. (B) Measurement of 
increased hPreP activity for pF1β in the presence of compound 3c at concentrations ranging 
from 100 to 0.01μM. The panel C demonstrated the representative gel image.
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Effect of compound 4c on pF1β degradation. (A) Densitometry of pF1β immunoreactive 
bands is shown using NIH ImageJ software. Determination of proteolytic activity of hPreP 
showing degradation of pF1β, pure hPreP protein was incubated with pF1β and various 
concentrations of compound 4c, which were then subjected to immunoblotting with 
antibody to F1β and detection with ECL to reveal immunoreactive biotin Aβ. (B) 
Measurement of increases in hPreP activity for pF1β in the presence of compound 4c at 
concentrations ranging from 100 to 0.01μM. The panel C demonstrated the representative 
gel image.
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Kinetics of degradation of fluorogenic Substrate V by hPreP in the presence of 
compound-3c at 1μM. (A) The change in fluorescence quenching was measured with 
excitation and emission wavelength set at 320 nm and 405 nm, respectively. (B) 
Measurement of increases in hPreP activity for Substrate V degradation in the presence of 
3c at concentrations ranging from 0.00001 to 5μM.
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Kinetics of degradation of the fluorogenic Substrate V by hPreP in the presence of 
compound-4c at 1μM. (A) The change in fluorescence quenching was measured with 
excitation and emission wavelength set at 320 nm and 405 nm, respectively. (B) 
Measurement of increases in hPreP activity for Substrate V degradation in the presence of 
4c at concentrations ranging from 0.00001 to 5μM.
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The change in magnitude of hPreP activity for three substrates. (A) Compound 3c & 4c 
showed folds increase respectively in the magnitude of hPreP activity for Aβ (1–42). 
Densitometry of Aβ (1–42) immunoreactive bands is shown. (B) Compound 3c & 4c show 
folds increase, respectively, in the magnitude of hPreP activity for pF1β (2–54). (C) 
Compound 3c & 4c show folds increase, respectively, in the magnitude of hPreP activity for 
substrate V.
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Selective synthesis of imidazole scaffold and selected molecular targets of human PreP 
activators.
Vangavaragu et al. Page 25

















































































































































































































































































































































































































































































Eur J Med Chem. Author manuscript; available in PMC 2015 April 09.
